Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali
Just two months ago, Novartis’ team turned up at ASCO with some clearly positive improved survival rates for a group of pre-menopausal breast cancer patients taking the CDK 4/6 drug Kisqali. And now they’re back, saying they also scored in a separate trial tracking OS among another group of post-menopausal women taking the blockbuster wannabe.
We won’t hear the details on the Monaleesa-3 data until they can be rolled out later at a scientific conference, but investigators say the drug scored on the key endpoint in first-line and second-line cases. And this expands on their boast for holding the first — though no longer the only — positive survival results in the field, something Novartis oncology chief Susanne Schaffert says she’s “thrilled” to see.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.